University of Texas System
Company
University of Texas System develops one asset. Mostly cell therapy acting on EGFR, KRAS and TP53.
- 1
- Asset
- Furthest stage
- Not known
- 346
- Trials
- 0
- Signals
Pipeline
1Sleeping Beauty immunotherapy program
Uses non-viral gene transfer to engineer T cells expressing T-cell receptors that recognize tumor-specific neoantigens.
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
4In the full profile
- Evidence behind the mechanisms3
- Trials386
- Similar companies6
Papers
SAT-785 Predictors Of Osteoporosis In Orthotopic Heart Transplant Recipients
ENDO 2025 abstract, Oct 23, 2025
Unraveling links between aging, circadian rhythm and cancer: Insights from evidence-based analysis
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, Jul 11, 2024
Medical principles and practice : international journal of the Kuwait University, Health Science Centre, Jun 2, 2023
Sarcopenia and Cardiovascular Diseases
Circulation, May 15, 2023
Exponential decrease during aging and random lifetime of mouse spermatogonial stem cells
Science (New York, N.Y.), Dec 15, 1978